



King Saud University
Arabian Journal of Chemistry

www.ksu.edu.sa
www.sciencedirect.com



ORIGINAL ARTICLE

Synthesis and antimicrobial activities of some novel 1,2,4-triazole derivatives

Yatin J. Mange^a, Arun M. Isloor^{a,*}, Shridhar Malladi^a, Shrikrishna Isloor^b,
Hoong-Kun Fun^{c,*}

^a Organic Chemistry Division, Department of Chemistry, National Institute of Technology, Surathkal, Mangalore 575 025, Karnataka, India

^b Department of Microbiology, Veterinary University, Hebbal, Bangalore, India

^c Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Kingdom of Saudi Arabia

Received 22 December 2010; accepted 31 January 2011
Available online 5 February 2011

KEYWORDS

1,2,4-Triazoles;
Schiff bases;
Antimicrobial activity

Abstract In the present investigation, a series of new Schiff bases **4a–f** were synthesized by the condensation of *N*-[4-amino-5-sulfanyl-4*H*-1,2,4-triazol-3-yl)methyl]-4-substituted-benzamides **3a–b** with various substituted aromatic aldehydes in ethanol–dioxane mixture using catalytic amount of sulfuric acid. The starting materials **3a–b** were in turn synthesized by the fusion of benzoyl glycine/substituted benzoylglycine with thiocarbohydrazide. Newly synthesized compounds were characterized by IR, NMR, mass spectra and elemental analyses. All the compounds were evaluated for their antibacterial and antifungal activity using the Minimum Inhibition Concentration (MIC) method by serial dilution technique. Few of the compounds were found to be biologically active.

© 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.

1. Introduction

Since last few decades, there is tremendous growth of research in the synthesis of nitrogen containing heterocyclic derivatives because of their utility in various applications, such as pharmaceuticals, propellants, explosives, pyrotechnics and especially in chemotherapy (Chavez and Parrish, 2009). A large number of ring systems containing 1,2,4-triazoles have been incorporated into a wide variety of therapeutically interesting drug candidates including anti-inflammatory, CNS stimulants, sedatives, anti-anxiety, antimicrobial agents (Nadkarni et al., 2001; Isloor et al., 2009), antimycotic agents such as Fluconazole, Itraconazole and Voriconazole (The Merck Index, 1996; Haber, 2001). Also there are some known drugs containing 1,2,4-triazole moiety, e.g. Triazolam (Brucato et al., 1978),

* Corresponding authors. Tel.: +91 824 2474000x3206; fax: +91 824 2474033.


E-mail address: isloor@yahoo.com (A.M. Isloor).

1878-5352 © 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.

Peer review under responsibility of King Saud University.
doi:10.1016/j.arabjc.2011.01.033



Production and hosting by Elsevier



4a: R=H, R¹= p-NO₂-C₆H₅; **4b:** R=H, R¹= p-OCH₃-C₆H₅; **4c:** R=CH₃, R¹= p-NO₂-C₆H₅;
4d: R=CH₃, R¹= p- OCH₃-C₆H₅; **4e:** R=CH₃, R¹= p- Cl-C₆H₅; **4f:** R=CH₃, R¹= 3,4- OCH₃-C₆H₅.

Scheme 1 Synthetic route for the Schiff bases **4a–f**.

Alprazolam (Coffen and Fryer, 1973), Etizolam (Shiroki et al., 1975), Furacylin (Povelista and Gural, 1973), Ribavirin (Sidwell et al., 1975), Hexaconazole (Shepherd, 1986), Triadimefon (Lye, 1987), Mycobutanil (Efthimiadis, 1988), Rizatriptan (Hart, 1999), Propiconazole (Reet et al., 1976), and Fluotrimazole (Worthington, 1984). 3-Substituted-4-amino-5-mercapto-1,2,4-triazoles by virtue of their ambient nucleophilic centre are good starting materials for the synthesis of several interesting N-bridged heterocycles. A detailed literature survey revealed that, Schiff bases possess diverse type of biological activities (El-Sayed, 2006). Some Schiff's bases bearing aryl groups or heterocyclic residues exhibited interesting biological activities, which has attracted many researchers' attention in recent years (Holla et al., 2000; Isloor et al., 2009; Marina et al., 2002). Keeping in view of the above facts and in continuation of our search on biologically potent molecules, we herein report the synthesis of some new 1,2,4-triazole derivatives and their antimicrobial activity.

2. Experimental

2.1. Measurements

Melting points were determined by open capillary method and are uncorrected. The IR spectra (in KBr pellets) were recorded on a Thermo Nicolet avatar 330-FT-IR spectrophotometer. ¹H NMR and ¹³C NMR spectra were recorded (DMSO-*d*₆) on a Bruker (400 MHz) spectrometer using TMS as internal standard. Chemical shift values are given in δ scales. The mass spectra were recorded on LC-MS-Agilent 1100 series and API 2000 LC/MS system. Elemental analyses were performed on a Flash EA 1112 series CHNS-O analyzer. The completion of the reaction was checked by thin layer chromatography (TLC) on silica gel coated aluminium sheets (Silica Gel 60 F254). Commercial grade solvents and reagents were used without further purification. The reaction pathway has been summarized in Scheme 1.

2.2. Synthesis

2.2.1. Synthesis of *N*-[(4-amino-5-sulfanyl-4*H*-1,2,4-triazol-3-yl)methyl]-4-substituted-benzamide **3a–b**

An equimolar mixture of *N*-benzoylglycine/*N*-(*p*-tolyl)glycine **2a** (0.01674 mol) and thiosemicarbazide **1** (0.01674 mol) were fused on oil bath for 1 h. Then the reaction mixture was cooled and treated with a cold solution of 5% NaHCO₃. The resulted solid was filtered, washed with water and recrystallised from ethanol.

2.2.1.1. *N*-[(4-Amino-5-sulfanyl-4*H*-1,2,4-triazol-3-yl)methyl]benzamide **3a** (Hassan, 2009). Yield 63.63%, m.p. 279–280 °C. IR (cm⁻¹) 3447, 3316 (N–H str), 3096 (C–H str), 1652 (C=O str), 1601 (C=N). ¹H NMR (DMSO-*d*₆) δ = 13.58 (s, 1H, S–H), 8.95 (t, 1H, N–H), 7.46–7.88 (m, 5H, Ar–H), 5.61 (s, 2H, –NH₂), 4.49 (d, 2H, –CH₂). MS (EI). *m/z* 250 [M + 1].

2.2.1.2. *N*-[(4-Amino-5-sulfanyl-4*H*-1,2,4-triazol-3-yl)methyl]-4-methylbenzamide **3b**. Yield 46.90%, m.p. 220–221 °C. IR (cm⁻¹) 3321, 3258 (N–H str), 3079 (C–H str), 1682 (C=O str), 1617 (C=N). ¹H NMR (DMSO-*d*₆) δ = 13.47 (s, 1H, S–H), 8.51 (t, 1H, N–H), 7.18–7.78 (m, 4H, Ar–H), 5.48 (s, 2H, –NH₂), 4.51 (d, 2H, –CH₂). MS (EI). *m/z* 264 [M + 1].

2.2.2. Synthesis of *N*-[(4-{[(*E*)-substituted]amino}-5-sulfanyl-4*H*-1,2,4-triazol-3-yl)methyl]-4-substituted-benzamide **4a–f**

Equimolar mixture of *N*-[(4-amino-5-sulfanyl-4*H*-1,2,4-triazol-3-yl)methyl]-4-substituted-benzamide **3a–b** (0.0004 mol), substituted benzaldehyde (0.0004 mol) and 2–3 drops of concentrated sulfuric acid in ethanol–dioxane mixture was refluxed for 6 h. The resulting solution was cooled to room temperature and the precipitated solid was filtered under suction, washed with cold ethanol and recrystallised from hot ethanol.

2.2.2.1. *N*-[4-{[(*E*)-(4-Nitrophenyl)methylidene]amino}-5-sulfanyl-4*H*-1,2,4-triazol-3-yl)methyl]benzamide **4a**. Yield 88.88%, m.p. 276–279 °C. IR (cm⁻¹) 3322 (N–H str), 3046 (C–H stretch), 1642 (C=O str), 1596 (C=N), 1277 (C=S). ¹H NMR (DMSO-*d*₆) δ = 13.99 (s, 1H, S–H), 10.4 (s, 1H, N=CH), 9.01 (t, 1H, N–H), 7.42–8.33 (m, 9H, Ar-H), 4.67 (d, 2H, –CH₂). ¹³C NMR (DMSO-*d*₆) δ = 166.3, 161.8, 158.9, 149.4, 148.8, 138.1, 133.6, 131.4, 129.6, 128.2, 127.2, 124.0, 34.2. MS [EI] *m/z* 383 [M + 1]. Elemental analysis (C₁₇H₁₄N₆O₃S); calcd. C, 53.40; H, 3.69; N, 21.98; found C, 53.36; H, 3.72; N, 21.95%.

2.2.2.2. *N*-[4-{[(*E*)-(4-Methoxyphenyl)methylidene]amino}-5-sulfanyl-4*H*-1,2,4-triazol-3-yl)methyl]benzamide **4b**. Yield 66.34%, m.p. 232–235 °C. IR (cm⁻¹) 3282 (N–H str), 3057 (C–H stretch), 1641 (C=O str), 1603 (C=N), 1251 (C=S). ¹H NMR (DMSO-*d*₆) δ = 13.82 (s, 1H, S–H), 9.78 (s, 1H, N=CH), 8.97 (t, 1H, N–H), 7.04–7.84 (m, 9H, Ar-H), 4.60 (d, 2H, –CH₂), 3.84 (s, 3H, –OCH₃). ¹³C NMR (DMSO-*d*₆) δ = 166.3, 163.2, 162.7, 161.6, 148.3, 133.7, 131.3, 130.6, 128.2, 127.2, 124.5, 114.5, 55.4, 34.3. MS [EI] *m/z* 368 [M + 1]. Elemental analysis (C₁₈H₁₇N₅O₂S); calcd. C, 58.84; H, 4.66; N, 19.06; found C, 58.80; H, 4.61; N, 19.09%.

2.2.2.3. 4-Methyl-*N*-[4-{[(*E*)-(4-nitrophenyl)methylidene]amino}-5-sulfanyl-4*H*-1,2,4-triazol-3-yl)methyl]benzamide **4c**. Yield 64.88%, m.p. 269–272 °C. IR (cm⁻¹) 3318 (N–H str), 3035.8 (C–H str), 1640 (C=O str), 1603 (C=N), 1276 (C=S). ¹H NMR (DMSO-*d*₆) δ = 13.99 (s, 1H, S–H), 10.41 (s, 1H, N=CH), 8.93 (t, 1H, N–H), 7.24–8.34 (m, 8H, Ar-H), 4.67 (d, 2H, –CH₂), 2.33 (s, 3H, CH₃). ¹³C NMR (DMSO-*d*₆) δ = 166.2, 161.8, 158.8, 149.3, 148.8, 141.3, 138.1, 130.8, 129.6, 128.8, 127.2, 124.0, 34.2, 20.8. MS [EI] *m/z* 397 [M + 1]. Elemental analysis (C₁₈H₁₆N₆O₃S); calcd. C, 54.54; H, 4.07; N, 21.20; found C, 54.59; H, 4.01; N, 21.25%.

2.2.2.4. *N*-[4-{[(*E*)-(4-Methoxyphenyl)methylidene]amino}-5-sulfanyl-4*H*-1,2,4-triazol-3-yl)methyl]-4-methylbenzamide **4d**. Yield 75.11%, m.p. 246–250 °C. IR (cm⁻¹) 3283 (N–H str), 3053 (C–H stretch), 1634 (C=O str), 1604 (C=N), 1246 (C=S). ¹H NMR (DMSO-*d*₆) δ = 13.68 (s, 1H, S–H), 10.12 (s, 1H, N=CH), 8.69 (t, 1H, N–H), 6.96–7.83 (m, 8H, Ar-H), 4.62 (d, 2H, –CH₂), 3.86 (s, 3H, –OCH₃), 2.38 (s, 3H, –CH₃). MS [EI] *m/z* 382 [M + 1]. Elemental analysis (C₁₉H₁₉N₅O₂S); calcd. C, 59.82; H, 5.02; N, 18.36; found C, 59.78; H, 5.06; N, 18.31%.

2.2.2.5. *N*-[4-{[(*E*)-(4-Chlorophenyl)methylidene]amino}-5-sulfanyl-4*H*-1,2,4-triazol-3-yl)methyl]-4-methylbenzamide **4e**. Yield 62.10%, m.p. 257–258.5 °C. IR (cm⁻¹) 3295 (N–H str), 3045 (C–H str), 1637 (C=O str), 1585 (C=N), 1274 (C=S). ¹H NMR (DMSO-*d*₆) δ = 13.94 (s, 1H, S–H), 10.08 (s, 1H, N=CH), 8.94 (t, 1H, N–H), 7.24–7.93 (m, 8H, Ar-H), 4.61 (d, 2H, –CH₂), 2.33 (s, 3H, –CH₃). ¹³C NMR (DMSO-*d*₆) δ = 166.2, 161.7, 161.3, 148.6, 141.4, 137.2, 131.0, 130.9, 130.2, 129.2, 128.8, 127.3, 34.2, 20.9. MS [EI] *m/z* 386. MS [EI] *m/z* 386 [M + 1]. Elemental analysis (C₁₈H₁₆ClN₅OS); calcd. C, 56.03; H, 4.18; N, 18.15; found C, 56.07; H, 4.12; N, 18.20%.

2.2.2.6. *N*-[4-{[(*E*)-(3,4-Dimethoxyphenyl)methylidene]amino}-5-sulfanyl-4*H*-1,2,4-triazol-3-yl)methyl]-4-meth-

ylbenzamide **4f**. Yield 81.62%, m.p. 231–235 °C. IR (cm⁻¹) 3372 (N–H stretch), 3052 (C–H stretch), 1653 (C=O str), 1595 (C=N), 1259 (C=S). ¹H NMR (DMSO-*d*₆) δ = 13.88 (s, 1H, S–H), 9.82 (s, 1H, N=CH), 8.92 (t, 1H, N–H), 7.06–7.75 (m, 7H, Ar-H), 4.64 (d, 2H, –CH₂), 2.33 (s, 3H, –CH₃), 3.74 (s, 3H, –OCH₃), 3.84 (s, 3H, –OCH₃). ¹³C NMR (DMSO-*d*₆) δ = 166.2, 163.0, 161.6, 152.7, 149.1, 148.4, 141.3, 131.0, 128.8, 127.3, 124.7, 124.6, 111.2, 108.8, 55.6, 55.3, 34.3, 20.9. MS [EI] *m/z* 412 [M + 1]. Elemental analysis (C₂₀H₂₁N₅O₃S); calcd. C, 58.38; H, 5.14; N, 17.02; found C, 58.41; H, 5.19; N, 17.07%.

2.3. Antimicrobial studies

All the newly synthesized compounds were evaluated for their antimicrobial activities against various microorganisms representing Gram-positive bacteria (*Staphylococcus aureus* and *Bacillus subtilis*), Gram-negative bacteria (*Escherichia coli* and *Pseudomonas aeruginosa*) and fungus (*Candida albicans*), using the Minimum Inhibition Concentration (MIC) method by the serial dilution technique (Mackie and McCartney, 1989). Several colonies of *S. aureus*, *B. subtilis*, *E. coli* and *P. aeruginosa* were picked off a fresh isolation plate and inoculated in corresponding tubes containing 5 mL of trypticase soya broth. The broth was incubated for 6 h at 37 °C until there was visible growth. Mc Farland No.5 standard was prepared by adding 0.05 mL of 1% w/v BaCl₂·2H₂O in Phosphate Buffered saline (PBS) to 9.95 mL of 1% v/v H₂SO₄ in PBS. The growth of all the four cultures was adjusted to Mc Farland No. 5 turbidity standard using sterile PBS. This gives a 10⁸ cfu/mL suspension. The working inoculums of above mentioned four different microorganisms containing 10⁵ cfu/mL suspension was prepared by diluting the 10⁸ cfu/mL suspension, 10³ times in trypticase soya broth.

Antimicrobial suspension was prepared by dissolving 0.5 µg of each compound in 10 mL of trypticase soya broth to get 50 µg/mL. This suspension was filter sterilized in syringe filters. To prepare the dilutions in all, for each of the eight anti-microbial compounds and standard antimicrobial i.e. Ceftriaxone, 24 tubes of 5 mL capacity were arranged in four rows with each row containing six tubes. Then 1.9 mL of trypticase soya broth was added in the first tube in each row and 1 mL in the remaining tubes. Now, 100 µL of filtered anti microbial suspension was added to the first tube in each row and after mixing the content, 1 mL was serially transferred from these tubes to the second tube in each of the rows. The contents in the second tube of each of the rows were mixed and transferred to the third tube in each of the rows. This serial dilution was repeated till the sixth tube in each of the rows. This provided anti microbial concentrations of 50, 25, 12.5, 6.25, 3.125, 1.6125 µg/mL in the first to sixth tube, respectively, in each row. Finally, 1 mL of 10⁵ cfu/mL of *S. aureus*, *B. subtilis*, *E. coli*, *P. aeruginosa* and *C. albicans* suspension were added to the first, second, third and fourth rows of tubes, respectively. Along with the test samples and Ceftriaxone (standard), the inoculum control (without antimicrobial compound) and broth control (without antimicrobial compound and inoculum) were maintained. All the test sample and control tubes were then incubated for 16 h at 37 °C. The results of the antimicrobial studies are summarized in Table 1.

Table 1 Antimicrobial activity of newly synthesized compounds.

Compound No.	Antibacterial (MIC, µg/mL)				Antifungal (MIC, µg/mL) <i>C. albicans</i>
	<i>S. aureus</i>	<i>B. subtilis</i>	<i>E. coli</i>	<i>P. aeruginosa</i>	
4a	3.125	3.125	3.125	3.125	1.6125
4b	3.125	3.125	3.125	3.125	3.125
4c	3.125	3.125	3.125	3.125	3.125
4d	3.125	3.125	3.125	3.125	3.125
4e	3.125	3.125	3.125	3.125	3.125
4f	3.125	3.125	25.00	25.00	1.6125
Ceftriaxone (standard)	3.125	1.6125	1.6125	1.6125	3.125
Inoculum control	Growth in all concentrations	Growth in all concentrations	Growth in all concentrations	Growth in all concentration	Growth in all concentrations
Broth control	No growth	No growth	No growth	No growth	No growth

3. Results and discussion

3.1. Chemistry

Formation of *N*-[4-[(*E*)-substituted]amino]-5-sulfanyl-4*H*-1,2,4-triazol-3-yl)methyl]-4-substituted-benzamide (**4**) was confirmed by recording their IR, NMR, mass spectra and elemental analyses. IR spectrum of compound **4a** showed absorption bands at 3322, 3046, 1642, 1596 and 1277 cm⁻¹ which is due to the N-H, C-H, C=O, C=N and C=S groups, respectively. The ¹H NMR spectrum of **4a** showed a singlet at δ 13.99 corresponds to S-H proton. A singlet at δ 10.4 was due to N=CH proton. A triplet was observed at δ 9.01 was due to N-H attached to -CH₂. The appearance of doublet at δ 4.67 and multiplet at δ 7.42–8.33 was due to -CH₂ and aromatic ring protons, respectively. Similarly the mass spectrum was recorded and reported as [M + 1] values. For the compound **4a**, molecular weight 383 is consistent with the molecular formula C₁₇H₁₄N₆O₃S. The values for the remaining compounds have been presented under the experimental part.

3.2. Antimicrobial activity

All the newly synthesized compounds were screened for their antibacterial and antifungal activities. For antibacterial studies, microorganisms employed were *S. aureus*, *B. subtilis*, *E. coli* and *P. aeruginosa*. For antifungal studies, microorganism employed was *C. albicans*. Both antimicrobial studies were assessed by Minimum Inhibition Concentration (MIC) method by the serial dilution technique.

From the antimicrobial activity study, it was found that, compounds **4a–f** exhibited the same activity as that of the standard drug Ceftriaxone against *S. aureus* and moderate activity against other bacteria *B. subtilis*, *E. coli*, *P. aeruginosa* and also fungus *C. albicans*. The observed activity may be due to presence of chloro, methoxy and nitro groups in these compounds. The antifungal activity of compounds **4a** and **4f** against *C. albicans* was found to be higher than that for the standard drug. However, remaining compounds exhibited same activity as that of standard drug. The observed activity in **4a** and **4f** is may be due to the presence of nitro group alone for the **4a**, and in **4f**, it may be due to the number and orientation of methoxy group.

4. Conclusion

A novel series of Schiff bases bearing 1,2,4-triazole ring systems were synthesized. These were characterized by IR, NMR, mass spectrometry study and elemental analyses. All the compounds were screened for their antibacterial and antifungal activity by serial dilution method. Compounds **4a–f** exhibited the same activity as that of the standard drug Ceftriaxone against *S. aureus*. Compounds **4a** and **4f** have showed excellent antifungal activity.

Acknowledgements

The Authors extend their appreciation to The Deanship of Scientific Research at King Saud University for the funding the work through the research group project No. RGP-VPP-207.

References

- Brucato, A., Copoola, A., Gianguzza, S., Provenzano, P.M., 1978. Bull. Soc. Ital. Sper. 54, 1051.
- Chavez, D.E., Parrish, D.A., 2009. J. Heterocycl. Chem. 46, 88–90.
- Coffen, D.L., Fryer, R.I., 1973. U.S. Patent 3,849,434, 1974, Chem. Abstr. 82, 730044v.
- Efthimiadis, P., 1988. In: Proceedings of British Crop Conference, Brighton, vol. 3, p. 887.
- Haber, J., 2001. Cas. Lek. Cesk. 140, 596–604.
- Hart, C., 1999. Drugs for migraine, In: Modern Drug Discovery, American Chemical Society.
- Hassan, A.Y., 2009. Phosphorus, Sulfur Silicon Relat. Elem. 184 (11), 2759–2776.
- Holla, B.S., Rao, B.S., Shridhara, K., Akberali, P.M., 2000. Farmaco 55, 338–344.
- Isloor, A.M., Kalluraya, B., Shetty, P., 2009. Eur. J. Med. Chem. 44, 3784–3787.
- Lye, H., 1987. Modern Selective Fungicides, Longman Scientific Technical, Harlow, pp. 13–30.
- Mackie, Mc Cartney., 1989. Practical Medical Microbiology, 13th ed. Churchill Livingstone Longman Group UK Limited, pp. 46–48.
- Marina, K., Anastssia, M., Panagiotis, M., Nicole, P., Spyroula, P.G., Christophe, P., Myriam, W., Erik, D.C., 2002. Farmaco 57, 253–257.
- Nadkarni, B.A., Kamat, V.R., Khadse, B.G., 2001. Arzneim. Forsch. 51, 569–573.

- Povelista, F.D., Gural, A.G., 1973. Antibiotiki (Mosc.) 18, 71; Chem. Abstr. 78, 93044.
- Reet, G.V., Heeres, J., Wals, L., 1976. Ger. Pat. 2,551,560, 1976; Chem. Abstr. 85, 94368.
- El-Sayed, R., 2006. Indian J. Chem. 45B, 738–746.
- Shepherd, M.C., 1986. In: Proceedings of British Crop Protection Conference, Brighton, vol. 1, p. 19.
- Shiroki, M., Tahara, T., Araki, K., 1975. Jap. Pat. 75100096.
- Sidwell, R.W., Allen, L.B., Hoffman, J.H., Witkowsti, J.T., Simon, L.N., 1975. Proc. Soc. Exp. Biol. Med. 148, 854–858.
- The Merck Index., 1996. 12th ed. Merck and Co. Inc., Whitehouse Station, New Jersey.
- Worthington, P.A., 1984. In: Proceedings of British Crop Protection Conference, Brighton, vol. 3, p. 955.